6-OHDA Rat Model of Parkinson's Disease

6-OHDA Rat Model of Parkinson's Disease

Overview

The 6-OHDA (6-hydroxydopamine) rat model is a classic toxin-based model of Parkinson's disease that produces selective destruction of catecholaminergic neurons[@ungerstedt1968]. Unlike the MPTP model, 6-OHDA is administered directly into the brain, producing precise, unilateral lesions that allow each animal to serve as its own control.

History

6-OHDA was first used to model PD in the 1960s by Ungerstedt, who demonstrated that bilateral injections produced a hypokinetic syndrome resembling parkinsonism. The unilateral model was later developed to allow for detailed behavioral and pharmacological studies[@dekundy2007].

Mechanism of Toxicity

Key Mechanisms

Model Variants

Unilateral Lesions

6-OHDA Rat Model of Parkinson's Disease

Overview

The 6-OHDA (6-hydroxydopamine) rat model is a classic toxin-based model of Parkinson's disease that produces selective destruction of catecholaminergic neurons[@ungerstedt1968]. Unlike the MPTP model, 6-OHDA is administered directly into the brain, producing precise, unilateral lesions that allow each animal to serve as its own control.

History

6-OHDA was first used to model PD in the 1960s by Ungerstedt, who demonstrated that bilateral injections produced a hypokinetic syndrome resembling parkinsonism. The unilateral model was later developed to allow for detailed behavioral and pharmacological studies[@dekundy2007].

Mechanism of Toxicity

Key Mechanisms

Model Variants

Unilateral Lesions

| Injection Site | Effect | Common Use |
|----------------|--------|------------|
| Medial forebrain bundle | >95% DA depletion | Rotation behavior |
| Substantia nigra | Partial SNc lesion | Selective degeneration |
| Striatum | Retrograde degeneration | Progressive model |

Bilateral Lesions

• Produces severe hypokinesia
• Often lethal due to dysphagia
• Used sparingly due to ethical concerns

Key Phenotypes

Motor Symptoms (Unilateral Model)

• Circling behavior: Rotation toward lesioned side (spontaneous)
• Apomorphine-induced rotation: Rotation toward intact side
• Cylinder test: Impaired forelimb use
• Stepping test: Deficit in adjustment steps

Non-Motor Symptoms

• Olfactory deficits: Early smell dysfunction
• Sleep abnormalities: REM sleep changes
• Anxiety-like behavior: Increased anxiety in open field

Neurochemical Changes

• Dopamine depletion: 90-99% in striatum
• TH activity: Severely reduced in SNc
• Norepinephrine: Variable depending on injection site

Advantages and Limitations

Advantages

| Advantage | Description |
|-----------|-------------|
| Precise lesion control | Direct brain injection |
| Self-control design | Unilateral model allows within-animal comparison |
| Behavioral readouts | Multiple validated behavioral tests |
| Drug screening | Rotation test for anti-parkinsonian drugs |
| Anatomical precision | Well-defined injection targets |

Limitations

| Limitation | Description |
|------------|-------------|
| Surgical procedure | Requires stereotaxic surgery |
| No Lewy bodies | Lacks protein inclusions |
| Acute lesion | Rapid degeneration, not chronic |
| Non-physiological | Direct toxin injection is not natural |

Research Applications

Behavioral Studies

The unilateral model allows quantification of:

• Circling behavior (spontaneous and drug-induced)
• Forelimb use in cylinder test
• Skilled reaching tasks
• Grid and stepping tests

Drug Screening

Used to test:

• Dopamine agonists
• MAO-B inhibitors
• Neuroprotective agents
• Gene therapy approaches

Mechanism Studies

Investigation of:

• Oxidative stress pathways
• [Neuroinflammation](/mechanisms/neuroinflammation) Neurotrophic factor signaling
• Compensatory mechanisms

References

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [MPTP Mouse Model](/models/mptp-mouse-model-parkinsons)
• [Alpha-Synuclein Transgenic Models](/models/a53t-alpha-synuclein-mouse-parkinsons)
• [Dopamine Pathways](/mechanisms/dopamine-metabolism-parkinsons)